This is a prospective observational cohort study of patients with a medical diagnosis of diabetes that will undergo clinically indicated kidney biopsies. The biopsy, along with blood and urine samples from our patients will enable the TRIDENT team to use high-throughput genomic analysis and associated genetic and biomarker testing to characterize those diabetic patients at highest risk for developing end-stage kidney failure versus those with more stable diabetic kidney disease. Our hope is to ultimately improve the lives of all patients with diabetic kidney disease and prevent diabetes-related kidney failure. Each participating clinical site will enroll participants for the TRIDENT study.

© The Trustees of the University of Pennsylvania | Site best viewed in a supported browser. | Report Accessibility Issues and Get Help | Privacy Policy | Site Design: PMACS Web Team.